Share on StockTwits

Several investment firms have updated their stock ratings and price targets on shares of Amedisys (NASDAQ: AMED) in the last week:

  • Amedisys had its price target raised by analysts at Piper Jaffray from $12.00 to $18.00. They now have a “neutral” rating on the stock.
  • Amedisys had its “underperform” rating reaffirmed by analysts at Credit Suisse. They now have a $17.00 price target on the stock, up previously from $9.00.
  • Amedisys had its “hold” rating reaffirmed by analysts at Deutsche Bank. They now have a $22.00 price target on the stock, up previously from $14.00.
  • Amedisys had its price target raised by analysts at Jefferies Group from $12.00 to $16.50. They now have a “hold” rating on the stock.
  • Amedisys had its “neutral” rating reaffirmed by analysts at SunTrust. They now have a $23.00 price target on the stock, up previously from $18.00.

Amedisys Inc (NASDAQ:AMED) traded down 0.14% during mid-day trading on Tuesday, hitting $21.60. 808,980 shares of the company’s stock traded hands. Amedisys Inc has a 52 week low of $12.60 and a 52 week high of $21.86. The stock’s 50-day moving average is $15.89 and its 200-day moving average is $15.10. The company’s market cap is $717.9 million.

Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.